Cryptocurrency payment adoption by compounding pharmacies — March 2026

PharmHunterJen said:

They are two different exemptions from the same federal requirements and they buy different things.

Genuinely useful, thank you. I had the facts and not the framework. I will report back once I have actually tried it.

Adding the clinical framing, because it changes how the question reads.

Compounding pharmacy response time test for compounded supply: I email customer service at odd hours to test responsiveness. A pharmacy that can't answer questions promptly is a red flag.

My current pharmacy: average response time 4 hours. They answered my questions about reconstitution thoroughly and professionally.

Communication quality is a proxy for operational quality. A pharmacy that communicates well is likely manufacturing well too.

sean_dublin said:

The trade-off is reversibility against privacy and there is no option that gives you both.

Regarding compounded supply compounding legality: compounding pharmacies can legally produce semaglutide and tirzepatide while these drugs remain on the FDA shortage list. If/when the shortage resolves, the legal landscape may change.

Stay informed. The FDA shortage list is updated regularly. Current status as of my last check: semaglutide partially resolved shortage, tirzepatide still in shortage. This directly impacts compounding availability.

Dr.SurgeonPGH said:

Resolution therefore closed the doors unevenly, and the asymmetry follows from the bulks lists.

503A vs 503B compounding pharmacies for compounded supply — this distinction matters enormously:

I strongly recommend 503B facilities. The FDA oversight and cGMP requirements mean more consistent product quality.

Moderator note: reminder that nothing in this thread is medical advice, and that clinical claims need a source. No action needed from anybody.